Abstract Background and aims Our hypothesis is that Klebsiella pneumoniae (Kp) Type VI Secretion System (T6SS), normally used for bacteria competition during host colonization have a collateral impact on the host inflammatory pathway (Fig1). Our specific aims are to: (i) Characterize the impact of bacterial type VI Secretion System (T6SS) on host gut inflammation (ii) Develop a screen to identify T6SS inhibitors. Methods In vivo experiments involve infecting mice with Kp wild type (WT) and T6SS mutants to evaluate gut inflammation and immune response. Metagenomic analysis of IBD and CRC patients' microbiota will be conducted to assess T6SS gene enrichment. The molecular mechanism of T6SS activity and LPS release will be explored using various imaging and biochemical techniques. High-throughput screening of small molecule inhibitors targeting T6SS assembly will be performed, followed by validation in cellular models. The role of bacteria in tumorigenesis is increasingly recognized, yet our understanding of the underlying mechanisms remains incomplete, hindering the identification of new therapeutic strategies. It is therefore critical to decipher the bacterial mechanisms and their impact on the host to identify pathways that can be targeted from both sides. Anticipated impact Our preliminary data have uncovered a novel role of Type VI Secretion System (T6SS) role in gut inflammation. Building on our extensive expertise of this specific system, we will employ a multidisciplinary approach to inhibit T6SS. Inhibiting the T6SS could prevent both gut inflammation and Enterobacteria competition advantage in the gut, therefore reducing dysbiosis. Moreover, inhibition of bacterial virulence factors is an attractive strategy to complement antibiotic and anti-inflammatory treatments already in use.
Read full abstract